VASO Vasomedical Inc.

Vaso Corporation Announces Termination of Business Combination Agreement with Achari Ventures Holdings Corp. I

Vaso Corporation Announces Termination of Business Combination Agreement with Achari Ventures Holdings Corp. I

PLAINVIEW, N.Y., Sept. 18, 2024 (GLOBE NEWSWIRE) --  Vaso Corporation (“Vaso”) (OTCQX: VASO) today announced that it has provided notice to Achari Ventures Holdings Corp. I (“Achari”) to terminate the Business Combination Agreement with Achari. The Company will continue to seek opportunities to increase stockholder value, including through internal growth, new partnerships, and strategic investments with a concentration on medical and IT service companies.

About Vaso Corporation

Vaso Corporation is a diversified medical technology company operating in three business segments:

  • IT Segment provides network and IT services through two operating units: NetWolves Network Services, a managed network services provider with an extensive, proprietary service platform to a broad base of customers; and VHC-IT, a service provider for healthcare application solutions from various vendors as well as related services, including implementation, management and support.
  • Professional Sales Service Segment provides sales service of capital medical equipment through a wholly owned subsidiary VasoHealthcare, currently serving as the exclusive sales representative of GE HealthCare diagnostic imaging and ultrasound products and services in certain market segments in the USA.
  • Equipment Segment manages and coordinates the design, manufacture and sales of proprietary medical equipment and software, as well as operates the Company's overseas assets including China-based subsidiaries.

Additional information is available on the Company's website at 

Forward Looking Statements

Except for any historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “optimistic”, “plans”, “potential”, “looking forward”, and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions, including the possibility of a downturn in the US economy and the continued impact of the COVID-19 pandemic; the effect of the dramatic changes taking place in IT and healthcare; continuation of the GEHC agreement; the impact of competitive technology and products and their pricing; medical insurance reimbursement policies; manufacturing or supplier problems; unforeseen difficulties and delays in product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

Investor Contact:

Michael J. Beecher

Investor Relations

Phone: 516-997-4600         

Email: 



EN
18/09/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vasomedical Inc.

 PRESS RELEASE

Vaso Corporation Announces Executive Leadership Appointments & Names N...

Vaso Corporation Announces Executive Leadership Appointments & Names New Vice Chairman to the Board of Directors PLAINVIEW, N.Y, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO), a leader in human capital, information technology and MedTech, today announced new executive appointments to the Vaso management team and Board of Directors, effective January 1, 2025. Jane Moen was appointed Vaso Corporation’s Chief Operating Officer. She will continue in her role as President of VasoHealthcare, a Vaso Corporation subsidiary. Ms. Moen has served as a Director of Vaso C...

 PRESS RELEASE

Vaso Corporation CEO Reflects on a Year of Growth and Innovation in En...

Vaso Corporation CEO Reflects on a Year of Growth and Innovation in End-of-Year Letter Setting the Tone for a Promising 2025  Vaso Corporation137 Commercial StreetPlainview, New York 11803Tel: (516) 997-4600 Fax: (516) 997-2299 NEWS RELEASE PLAINVIEW, N.Y., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO), a leader in human capital, information technology and MedTech, today released a letter to shareholders and employees summarizing the company’s achievements throughout the year and outlining key strategic developments and priorities for the upcoming year. Hig...

 PRESS RELEASE

Vaso Corporation Announces Financial Results for Third Quarter 2024

Vaso Corporation Announces Financial Results for Third Quarter 2024 PLAINVIEW, N.Y., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO), a leading medtech company with a diversified business portfolio in network and healthcare IT services, professional sales services, and proprietary medical products, today reported its operating results for the three months ended September 30, 2024. “For the third quarter of 2024, the Company’s revenue was $20.8 million, an increase of 7% when compared to the prior year’s third quarter revenue of $19.4 million, mainly due to highe...

 PRESS RELEASE

Vaso Corporation Announces Termination of Business Combination Agreeme...

Vaso Corporation Announces Termination of Business Combination Agreement with Achari Ventures Holdings Corp. I PLAINVIEW, N.Y., Sept. 18, 2024 (GLOBE NEWSWIRE) --  Vaso Corporation (“Vaso”) (OTCQX: VASO) today announced that it has provided notice to Achari Ventures Holdings Corp. I (“Achari”) to terminate the Business Combination Agreement with Achari. The Company will continue to seek opportunities to increase stockholder value, including through internal growth, new partnerships, and strategic investments with a concentration on medical and IT service companies. About Vaso Corporati...

 PRESS RELEASE

Vaso Corporation Announces Date Change for Its Stockholders Meeting

Vaso Corporation Announces Date Change for Its Stockholders Meeting PLAINVIEW, N.Y., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO) today announced that at its special stockholders meeting on August 26, 2024, the meeting was adjourned without any consideration of the proposals to 10:00 AM Eastern on September 10, 2024 at the same location, the Lever House located at 390 Park Avenue, New York, NY 10022.   With the adjourned date being well after the Labor Day holiday, it will provide more stockholders with the opportunity to attend the stockholders meeting in pe...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch